SI2697227T1 - Kondenzirani derivati imidazola, uporabni kot ido inhibitorji - Google Patents

Kondenzirani derivati imidazola, uporabni kot ido inhibitorji

Info

Publication number
SI2697227T1
SI2697227T1 SI201230515A SI201230515A SI2697227T1 SI 2697227 T1 SI2697227 T1 SI 2697227T1 SI 201230515 A SI201230515 A SI 201230515A SI 201230515 A SI201230515 A SI 201230515A SI 2697227 T1 SI2697227 T1 SI 2697227T1
Authority
SI
Slovenia
Prior art keywords
imidazole derivatives
derivatives useful
ido inhibitors
fused imidazole
fused
Prior art date
Application number
SI201230515A
Other languages
English (en)
Slovenian (sl)
Inventor
Mario Mautino
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Tanay Kesharwani
Xiaoxia Zhang
Original Assignee
Newlink Genetics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corporation filed Critical Newlink Genetics Corporation
Publication of SI2697227T1 publication Critical patent/SI2697227T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201230515A 2011-04-15 2012-04-12 Kondenzirani derivati imidazola, uporabni kot ido inhibitorji SI2697227T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161475788P 2011-04-15 2011-04-15
PCT/US2012/033245 WO2012142237A1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors
EP15197593.5A EP3018132B1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors

Publications (1)

Publication Number Publication Date
SI2697227T1 true SI2697227T1 (sl) 2016-06-30

Family

ID=45976556

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201230515A SI2697227T1 (sl) 2011-04-15 2012-04-12 Kondenzirani derivati imidazola, uporabni kot ido inhibitorji
SI201231193T SI3018132T1 (en) 2011-04-15 2012-04-12 Condensed imidazole derivatives useful as IDO inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201231193T SI3018132T1 (en) 2011-04-15 2012-04-12 Condensed imidazole derivatives useful as IDO inhibitors

Country Status (30)

Country Link
US (5) US9260434B2 (https=)
EP (3) EP3348558A1 (https=)
JP (4) JP2014511876A (https=)
KR (1) KR102164443B1 (https=)
CN (2) CN103547579B (https=)
AU (4) AU2012242871C1 (https=)
BR (1) BR112013026494A2 (https=)
CA (1) CA2833296C (https=)
CL (1) CL2013002990A1 (https=)
CO (1) CO6862146A2 (https=)
CY (1) CY1117440T1 (https=)
DK (2) DK3018132T3 (https=)
ES (2) ES2660831T3 (https=)
HK (1) HK1256355A1 (https=)
HR (2) HRP20160369T1 (https=)
HU (2) HUE038586T2 (https=)
IL (3) IL228862A (https=)
LT (1) LT3018132T (https=)
ME (1) ME02417B (https=)
MX (1) MX340442B (https=)
NO (1) NO2694640T3 (https=)
NZ (2) NZ708090A (https=)
PE (2) PE20181023A1 (https=)
PL (2) PL2697227T3 (https=)
PT (1) PT3018132T (https=)
RS (2) RS54723B1 (https=)
RU (2) RU2017107026A (https=)
SI (2) SI2697227T1 (https=)
SM (1) SMT201600130B (https=)
WO (1) WO2012142237A1 (https=)

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (https=) 2011-04-15 2018-03-17
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
KR20150126623A (ko) 2013-03-14 2015-11-12 뉮링크 제넀틱슀 윔퍌레읎션 튞늜토판 ëŒ€ì‚ŹëĄœ 읞한 멎역얔제의 ì–”ì œì œëĄœì„œì˜ 삌환식 í™”í•©ëŹŒ
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN103382187B (zh) * 2013-08-06 2015-06-03 äżĄćźžç”Ÿç‰©ćŒ»èŻïŒˆäžŠæ”·ïŒ‰æœ‰é™ć…Źćž 侀种3-æ°Ż-7(5)-æșŽè‹Żćč¶ćŒ‚æ¶ć”‘çš„ćˆæˆæ–čæł•
KR102457145B1 (ko) 2013-12-24 2022-10-19 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ íŠžëŠŹì‹œíŽëŠ­ í™”í•©ëŹŒ
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
CA2956465A1 (en) * 2014-09-05 2016-03-10 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
CN107148425B (zh) 2014-10-29 2021-08-03 æ‹œæ–Żç§‘é˜żèżȘæœ‰é™ć…Źćž ćŻčmt1-mmpç‰čćŒ‚æ€§çš„ćŒçŽŻè‚œé…äœ“
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ïŒŽïœ‰ïœ‡ïœ‰ïœ”ă«ćŻŸă™ă‚‹æŠ—äœ“
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CN105884828A (zh) * 2015-02-16 2016-08-24 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
EA037112B1 (ru) 2015-03-02 2021-02-08 Đ ĐžĐłĐ”Đ»ŃŒ Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалс, Đ˜ĐœĐș. Đ˜ĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Ń‹ tgf-
KR20170134981A (ko) 2015-04-03 2017-12-07 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 암의 ìč˜ëŁŒë„Œ 위한 ìžëŒì•„ëŻŒ-2,3-디옄시êČŒë‚˜ì œì˜ 얔제제
TW201642897A (zh) 2015-04-08 2016-12-16  æ˜Ÿç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž ïŒšïœ…ïœ’ïŒ’ç”ćˆćŠ‘æȻ療
TWI698435B (zh) 2015-04-10 2020-07-11 è‹±ć±Źé–‹æ›ŒçŸ€ćł¶ć•†ç™ŸæżŸç„žć·žæœ‰é™ć…Źćž 䜜ç‚șćČ據èƒș,-äșŒćŠ æ°§é…¶ć’Œ/或è‰Č氚酞,-äșŒćŠ æ°§é…¶æŠ‘ćˆ¶ćŠ‘äč‹æ–°ç©Žäč‹ïŒ•æˆ–-ć–ä»Łäč‹ć’Șć”‘äžŠïŒ»ïŒ‘ïŒŒïŒ•ïŒïœïŒœćĄć•¶
CN108026098B (zh) * 2015-04-12 2019-09-03 æ­ć·žè‹±ćˆ›ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 䜜äžșido撌tdoæŠ‘ćˆ¶ć‰‚çš„æ‚çŽŻćŒ–ćˆç‰©
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3287461B1 (en) * 2015-04-21 2020-03-18 Jiangsu Hengrui Medicine Co., Ltd. Imidazo isoindole derivative, preparation method therefor and medical use thereof
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
ES2770349T3 (es) 2015-05-12 2020-07-01 Bristol Myers Squibb Co Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplĂĄsicos
DK3303396T5 (da) 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (zh) * 2015-06-18 2019-03-08 æˆéƒœæ”·ćˆ›èŻäžšæœ‰é™ć…Źćž äž€ç§æ°˜ä»Łçš„idoæŠ‘ćˆ¶ć‰‚ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
CN107922500A (zh) 2015-06-29 2018-04-17 æŽ›ć…‹èČ拒性歊 ć…·æœ‰ćąžćŒșçš„æż€ćŠšć‰‚æŽ»æ€§çš„æŠ—cd40抗䜓
CN105037371A (zh) * 2015-06-30 2015-11-11 è„żćŽć€§ć­Š äž€ç§æ°˜ä»Łçš„ćČ據èƒș-2,3-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
EP4659747A2 (en) 2015-07-24 2025-12-10 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
US10399987B2 (en) 2015-07-28 2019-09-03 Bristol-Myer Squibb Company TGF beta receptor antagonists
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN108349976A (zh) 2015-08-25 2018-07-31 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž TGFÎČć—äœ“æ‹źæŠ—ć‰‚
CN106478634B (zh) * 2015-09-01 2020-05-22 ć°šćŽćŒ»èŻç§‘æŠ€(æ±Ÿè„ż)æœ‰é™ć…Źćž 皠搈ć’Șć”‘ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ć’Œç”šé€”
US10308647B2 (en) 2015-10-29 2019-06-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as IDO/TDO inhibitors
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
JP2018532406A (ja) * 2015-11-09 2018-11-08 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒïŒŠïŒŽ ïŒšïœïœ†ïœ†ïœïœïœŽïœŽâˆ’ïŒŹïœ ïŒČ ïŒĄïœ‹ïœ”ïœ‰ïœ…ïœŽïœ‡ïœ…ïœ“ïœ…ïœŒïœŒïœ“ïœƒïœˆïœïœ†ïœ” ïŒ©ïœ„ïœïŒ‘ăŠă‚ˆăłïŒăŸăŸăŻïœ”ïœ„ïœäżźéŁŸć› ć­ă‚’ćŒćźšă™ă‚‹ăŸă‚ăźă‚čクăƒȘăƒŒăƒ‹ăƒłă‚°ă‚ąăƒƒă‚»ă‚€
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
MX2018006181A (es) 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
JP6856648B2 (ja) 2015-12-15 2021-04-07 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ïŒŁïœ˜ïœƒïœ’ïŒ”ć—ćźčäœ“ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čト
CN110072864B (zh) * 2015-12-24 2022-05-27 ćŸșć› æł°ć…‹ć…Źćž Tdo2æŠ‘ćˆ¶ć‰‚
CN107056785B (zh) * 2016-01-02 2021-06-22 æ­ć·žè‹±ćˆ›ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 䜜äžșido撌tdoæŠ‘ćˆ¶ć‰‚çš„æ‚çŽŻćŒ–ćˆç‰©
US20190031665A1 (en) * 2016-02-02 2019-01-31 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
TW201736373A (zh) * 2016-02-19 2017-10-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd 䜜ç‚șć…ç–«èȘżçŻ€ćŠ‘çš„äž‰äžŠç’°ćŒ–ćˆç‰©
EP3418282A4 (en) * 2016-02-19 2019-01-09 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. TRICYCLIC CONNECTION AS IMMUNOMODULATOR
WO2017140835A1 (en) 2016-02-19 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
CN105732643A (zh) * 2016-04-18 2016-07-06 è‹ć·žć€§ć­Š äž€ç§ć¶è”ç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćœšćˆ¶ć€‡idoé…¶æŠ‘ćˆ¶ć‰‚ć’Œéžç”Ÿäœ“æŠ—ç‚ŽèŻç‰©äž­çš„ćș”甚
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CN107312005B (zh) * 2016-04-27 2021-12-17 äžŠæ”·çż°æŁźç”Ÿç‰©ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć…·æœ‰ido/tdoæŠ‘ćˆ¶æŽ»æ€§çš„çš ćˆć’Șć”‘èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
WO2017192840A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017192844A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3452450A1 (en) 2016-05-04 2019-03-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190004743A (ko) 2016-05-04 2019-01-14 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 ìžëŒì•„ëŻŒ 2,3-디옄시êČŒë‚˜ì œì˜ 얔제제 및 귞의 ì‚Źìš© ë°©ëȕ
WO2017192813A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4ćŒ»èŻć…Źćž 甹äșŽé¶è›‹ç™œé™è§Łçš„èƒșèżžæŽ„çš„c3-戊äșŒé…°äșšèƒșé™è§Łć†łćźšć­äœ“
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc DegronĂ­meros espirocĂ­clicos para la degradaciĂłn de proteĂ­nas diana
CN109641874A (zh) 2016-05-10 2019-04-16 C4ćŒ»èŻć…Źćž 甹äșŽé¶è›‹ç™œé™è§Łçš„c3-çąłèżžæŽ„çš„æˆŠäșŒé…°äșšèƒșé™è§Łć†łćźšć­äœ“
CN107383012B (zh) * 2016-05-16 2021-09-28 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 搫äșŒçŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN105902542A (zh) * 2016-05-16 2016-08-31 ćŒ é˜ł äž€ç§ć¶è”ç‰©ćœšćˆ¶ć€‡æČ»ç–—ćżƒèĄ€çźĄç–Ÿç—…èŻç‰©äž­çš„ćș”甚
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN107556316B (zh) * 2016-06-30 2021-11-12 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN106957318B (zh) * 2016-05-19 2019-12-10 äž­ć›œç§‘ć­Šé™ąäžŠæ”·æœ‰æœșćŒ–ć­Šç ”ç©¶æ‰€ çš ćˆć€šçŽŻćČć“šć•‰ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ćŠćș”甚
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
AR108586A1 (es) 2016-06-10 2018-09-05 Lilly Co Eli Compuestos de 2,3-dihidro-1h-indol
CN107488179B (zh) * 2016-06-11 2024-06-07 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN107556315B (zh) * 2016-06-30 2021-08-31 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«ć››ć…ƒçŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN109757103B (zh) 2016-07-14 2024-01-02 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 针ćŻčtim3çš„æŠ—äœ“ćŠć…¶ç”šé€”
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) * 2016-07-29 2018-02-06 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
CN107698594A (zh) * 2016-08-09 2018-02-16 è‹ć·žć›œćŒĄćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ćČ據èƒș23â€‘ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚ćŠć…¶ćœšèŻć­Šäž­çš„ç”šé€”
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107383024B (zh) * 2016-09-12 2018-06-08 ćčżć·žćż…莝ç‰čćŒ»èŻæŠ€æœŻæœ‰é™ć…Źćž 搫ć’Șć”‘çš ćˆäž‰çŽŻç±»ćŒ–ćˆç‰©ćŠć…¶ćș”甚
TW201815766A (zh) 2016-09-22 2018-05-01 çŸŽć•†æ™źé›·èŸ›è‚Żć…Źćž ç”šæ–Œïœ‰ïœ„ïœćŠïœ”ïœ„ïœèȘżçŻ€äč‹ćŒ–ćˆç‰©ćŠæ–čæł•ä»„ćŠć…¶é©æ‡‰ç—‡
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
JP7623784B2 (ja) 2016-10-13 2025-01-29 ă‚žăƒ„ăƒŽăƒŒ ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ トăƒȘăƒ—ăƒˆăƒ•ă‚Ąăƒłä»ŁèŹç”Œè·ŻèȘżçŻ€ć‰€ă‚’ć«ă‚€ć…ç–«ç™‚æł•ăźæ–čæł•ăŠă‚ˆăłç”„æˆç‰©
CN108778332B (zh) * 2016-10-21 2019-10-18 è‹ć·žç››èżȘäșšç”Ÿç‰©ćŒ»èŻæœ‰é™ć…Źćž Pd-1抗䜓䞎idoæŠ‘ćˆ¶ć‰‚è”ćˆćœšćˆ¶ć€‡æŠ—è‚żç˜€çš„èŻç‰©äž­çš„ç”šé€”
TW201815793A (zh) * 2016-10-21 2018-05-01 æ±Ÿè˜‡æ†ç‘žé†«è—„è‚Ąä»œæœ‰é™ć…Źćž 侀繼ć’Ș攑侩異ćČć“šéĄžèĄç”Ÿç‰©çš„éŠé›ąéčŒçš„ç”æ™¶ćœąćŒćŠć…¶èŁœć‚™æ–čæł•
CN110139852A (zh) 2016-11-04 2019-08-16 ć„„ć…‹ć…°è”ćˆæœćŠĄæœ‰é™ć…Źćž äž‰çŽŻæ‚çŽŻèĄç”Ÿç‰©ćŠć…¶ç”šé€”
CN106474468B (zh) * 2016-11-23 2020-03-27 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŒ»ć­Šç”Ÿç‰©ć­Šç ”ç©¶æ‰€ äž€ç§ć€ćˆäœć‰‚ă€ć«èŻ„ć€ćˆäœć‰‚çš„ç–«è‹—ćŠç–«è‹—çš„ćˆ¶ć€‡æ–čæł•
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
US10604529B2 (en) 2016-12-20 2020-03-31 Shenzhen Chipscreen Biosciences Co., Ltd. Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
CN114989205A (zh) 2016-12-22 2022-09-02 ćĄé‡ŒćĄžæ‹‰ç”Ÿç‰©ç§‘ć­Šè‚Ąä»œć…Źćž 甹äșŽæŠ‘ćˆ¶çČŸæ°šé…žé…¶æŽ»æ€§çš„ç»„ćˆç‰©ć’Œæ–čæł•
CN108239091B (zh) * 2016-12-26 2021-08-13 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąèŻç‰©ç ”ç©¶æ‰€ 1-环深ćŸș-2-(5H-ć’Ș攑[5,1-a]ćŒ‚ćČ據)äč™ćŸș-1-é…źçš„æ‹†ćˆ†
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CA3047002A1 (en) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
CN110709420A (zh) 2017-03-31 2020-01-17 戊瑞æČ»ç–—æœ‰é™ć…Źćž äœżç”šæŠ—gitræŠ—äœ“çš„ç™Œç—‡ç»„ćˆç–—æł•
TWI788340B (zh) 2017-04-07 2023-01-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž 抗icosäżƒæ•ˆćŠ‘æŠ—é«”ćŠć…¶ç”šé€”
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
KR20190139216A (ko) 2017-04-28 2019-12-17 파읎람 프띌임 테띌퓚틱슀, ìžíŹ. Cd80 ì„žíŹì™ž 도메읞 íŽëŠŹíŽ©í‹°ë“œë„Œ 읎용한 ìč˜ëŁŒ ë°©ëȕ
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) * 2017-05-31 2019-11-12 æˆéƒœæ”·ćšé”èŻäžšæœ‰é™ć…Źćž 侀种idoæŠ‘ćˆ¶ć‰‚ćŒ–ćˆç‰©ă€èŻç”šç»„ćˆç‰©ă€ç”šé€”
CN110769822A (zh) 2017-06-20 2020-02-07 C4ćŒ»èŻć…Źćž 甹äșŽè›‹ç™œé™è§Łçš„n/o-èżžæŽ„çš„é™è§Łć†łćźšć­ć’Œé™è§Łć†łćźšć­äœ“
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
EP3645537A1 (en) 2017-06-28 2020-05-06 Genentech, Inc. Tdo2 and ido1 inhibitors
WO2019005559A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
EP3644993B1 (en) 2017-06-30 2023-08-02 Bristol-Myers Squibb Company Amorphous and crystalline forms of ido inhibitors
JP7186764B2 (ja) 2017-07-28 2022-12-09 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ æŠ—ç™Œć‰€ăšă—ăŠăźç’°çŠ¶ă‚žăƒŒă‚ŻăƒŹă‚Șチド
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
JP7670481B2 (ja) 2017-08-04 2025-04-30 ăƒă‚€ă‚čă‚Żăƒ«ăƒ†ă‚Żă‚č・ăƒȘミテッド ïŒŁïœ„ïŒ‘ïŒ“ïŒ—ă«ćŻŸă—ăŠç‰č異的ăȘäșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘガンド
CN109983019B (zh) * 2017-08-08 2021-12-21 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©çš„ćˆ¶ć€‡æ–čæł•
CN109384791B (zh) * 2017-08-09 2020-09-11 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©æžžçŠ»çą±çš„æ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
TW201920202A (zh) 2017-08-17 2019-06-01 ç‘žćŁ«ć•†æ„›æœè„żäșžèŁœè—„æœ‰é™ć…Źćž ćČ據èƒș2,3-äșŒæ°§é…¶ćŠ/或è‰Čèƒș酾2,3-äșŒæ°§é…¶çš„æŠ‘ćˆ¶ćŠ‘
BR112020003116A2 (pt) 2017-08-17 2020-08-04 Ikena Oncology, Inc. inibidores de ahr e usos dos mesmos
EP3670518A4 (en) 2017-08-18 2021-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TRICYCLIC COMPOUND CRYSTALS
CN111051305A (zh) * 2017-08-22 2020-04-21 ć‰ćˆ©ćŸ·ç§‘ć­Šć…Źćž æČ»ç–—æ€§æ‚çŽŻćŒ–ćˆç‰©
KR102812783B1 (ko) 2017-08-31 2025-05-26 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ 시큎늭 디뉎큎레였티드
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ æŠ—ç™Œć‰€ăšă—ăŠăźç’°çŠ¶ă‚žăƒŒă‚ŻăƒŹă‚Șチド
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN107501272B (zh) * 2017-09-05 2020-03-31 äž­ć›œèŻç§‘ć€§ć­Š ć’Ș攑ćč¶ćŒ‚ćČć“šç±»ido1æŠ‘ćˆ¶ć‰‚ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćș”甚
JP2020534289A (ja) 2017-09-14 2020-11-26 ăƒ©ăƒłă‚±ăƒŠăƒŒ ă‚€ăƒłă‚čăƒ†ă‚Łăƒ†ăƒ„ăƒŒăƒˆ ăƒ•ă‚©ăƒŒ ăƒĄăƒ‡ă‚Łă‚«ăƒ« ăƒȘă‚”ăƒŒăƒ がんぼæČ»ç™‚ăźăŸă‚ăźæ–čæł•ăŠă‚ˆăłç”„æˆç‰©
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US11660311B2 (en) 2017-10-10 2023-05-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3697801B1 (en) 2017-10-16 2024-11-20 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7306634B2 (ja) 2017-10-19 2023-07-11 äž€èˆŹç€Ÿć›Łæł•äșșăƒ•ă‚Ąăƒ«ăƒžăƒăƒŹăƒŒăƒ—ăƒ­ă‚žă‚§ă‚Żăƒˆæ”ŻæŽæ©Ÿæ§‹ ïŒ©ïœ„ïœïŒïœ”ïœ„ïœé˜»ćźłć‰€
JP2021501801A (ja) 2017-11-01 2021-01-21 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ç™Œăźć‡Šçœźă«ç”šă„ă‚‹ăŸă‚ăźć…ç–«ćˆșæż€ă‚ąă‚Žăƒ‹ă‚čăƒˆæŠ—äœ“
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
CN111386114A (zh) 2017-11-25 2020-07-07 ç™Ÿæ”Žç„žć·žæœ‰é™ć…Źćž 䜜äžșćČ據èƒș2,3-ćŒćŠ æ°§é…¶çš„é€‰æ‹©æ€§æŠ‘ćˆ¶ć‰‚çš„æ–°éą–è‹Żćč¶ć’Ș攑
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN111788227B (zh) 2017-12-27 2025-02-25 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 抗cd40æŠ—äœ“ćŠć…¶ç”šé€”
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
ES2907282T3 (es) 2018-01-15 2022-04-22 Idorsia Pharmaceuticals Ltd Inhibidores de la indoleamina 2,3-dioxigenasa y/o de la triptĂłfano dioxigenasa
WO2019141095A1 (zh) * 2018-01-19 2019-07-25 ć››ć·ç§‘äŒŠćšæł°ç”Ÿç‰©ćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž è„’ç±»ć’Œèƒç±»èĄç”Ÿç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠć…¶ćœšćŒ»èŻäžŠçš„ćș”甚
JP7229257B2 (ja) 2018-01-29 2023-02-28 ăƒĄăƒ«ă‚Ż パテント ă‚ČăƒŒă‚šăƒ ăƒ™ăƒŒăƒăƒŒ ïŒ§ïœƒïœŽïŒ’é˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”š
BR112020015396A2 (pt) 2018-01-29 2020-12-08 Merck Patent Gmbh Inididores de gcn2 e usos dos mesmos
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN111902429A (zh) 2018-02-23 2020-11-06 æ‹œæ–Żç§‘æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž ć€šèšäœ“ćŒçŽŻè‚œé…äœ“
ES2980374T3 (es) 2018-03-08 2024-10-01 Bristol Myers Squibb Co DinucleĂłtidos cĂ­clicos como agentes anticancerosos
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, åcido nucleico, composiçÔes, célula e métodos para preparar um anticorpo, para tratar cùncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficåcia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficåcia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar cùncer
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticùncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
JP2021522211A (ja) 2018-04-16 2021-08-30 ケăƒȘăƒŒă‚ș ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ„ïœïŒ”é˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”š
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
KR102767739B1 (ko) 2018-06-27 2025-02-12 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 T ì„žíŹ í™œì„±í™”ì œëĄœì„œ 유용한 ìč˜í™˜ëœ ë‚˜í”„í‹°ëŠŹë””ë…Œ í™”í•©ëŹŒ
CN112585139B (zh) 2018-06-27 2023-12-01 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 甚䜜tç»†èƒžæż€æŽ»ć‰‚çš„è˜ć•¶é…źćŒ–ćˆç‰©
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞æČ»ç–—æœ‰é™ć…Źćž ç»“ćˆćˆ°ilt4的抗䜓
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
CN116574105B (zh) 2018-09-27 2025-10-10 æ·±ćœłćŸźèŠŻç”Ÿç‰©ç§‘æŠ€è‚Ąä»œæœ‰é™ć…Źćž ć…·æœ‰ćČ據èƒș-2,3-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶æŽ»æ€§çš„ć–čć•‰èĄç”Ÿç‰©
CN113164780A (zh) 2018-10-10 2021-07-23 æł°æŽ›æ–ŻæČ»ç–—ć…Źćž 抗lapæŠ—äœ“ć˜äœ“ćŠć…¶ç”šé€”
CN113316590B (zh) 2018-11-16 2025-02-28 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 抗nkg2aæŠ—äœ“ćŠć…¶ç”šé€”
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CN120698983A (zh) 2018-12-20 2025-09-26 C4ćŒ»èŻć…Źćž é¶ć‘è›‹ç™œé™è§Ł
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
CN113795264A (zh) 2019-03-19 2021-12-14 ç“Šć°”ćžŒäŒŻäŒŠç§äșșè‚żç˜€ç ”ç©¶ćŸș金䌚 采甹Omomycć’Œç»“ćˆPD-1或CTLA-4的抗䜓æČ»ç–—ç™Œç—‡çš„è”ćˆç–—æł•
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
CN120574283A (zh) 2019-04-05 2025-09-02 懯éșŠæ‹‰ćŒ»ç–—ć…Źćž Staté™è§Łć‰‚ć’Œć…¶ç”šé€”
US20230295087A1 (en) 2019-05-13 2023-09-21 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
US12012374B2 (en) 2019-05-13 2024-06-18 Bristol-Myers Squibb Company Agonists of ROR GAMMAt
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3997083A1 (en) 2019-07-11 2022-05-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TWI860386B (zh) 2019-07-30 2024-11-01 è‹±ć•†æ‹œè„żćŻæł°ć…‹æ–Żæœ‰é™ć…Źćž 異èłȘé›™ç’°è‚œè€‡ćˆç‰©
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos Ăștiles como activadores de cĂ©lulas t
MX2022002877A (es) 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
JP7629459B2 (ja) 2019-11-19 2025-02-13 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ïŒšïœ…ïœŒïœ‰ïœïœ“ă‚żăƒłăƒ‘ă‚ŻèłȘăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘćŒ–ćˆç‰©
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
BR112022009944A2 (pt) 2019-11-26 2022-08-09 Bristol Myers Squibb Co Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN111333653A (zh) * 2019-12-16 2020-06-26 ć±±äžœć€§ć­Š 侀种icdèŻ±ćŻŒć‰‚-idoæŠ‘ćˆ¶ć‰‚çŒ€ćˆç‰©ćŠćˆ¶ć€‡æ–čæł•äžŽćș”甚
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
KR20220145325A (ko) 2019-12-17 2022-10-28 ìčŽìŽë©”띌 쎄띌퓚틱슀 ìžìœ”íŹë ˆìŽí‹°ë“œ Irak 분핎제 및 읎의 용도
KR20220119456A (ko) 2019-12-23 2022-08-29 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 T ì„žíŹ í™œì„±í™”ì œëĄœì„œ 유용한 ìč˜í™˜ëœ 퀮놀멬녾닐 플페띌진 í™”í•©ëŹŒ
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicĂ­clicos sustituidos Ăștiles como activadores de cĂ©lulas t
BR112022012204A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Compostos de heteroarila substituĂ­da Ășteis como ativadores de cĂ©lula t
BR112022012179A2 (pt) 2019-12-23 2022-09-06 Bristol Myers Squibb Co Compostos de quinazolina substituĂ­da Ășteis como ativadores de cĂ©lula t
EP4081308A4 (en) 2019-12-23 2024-01-24 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
KR20230020379A (ko) 2020-01-06 2023-02-10 하읎파읎바읎였 (에읎ìč˜ìŒ€ìŽ) 멬믾티드 항-tnfr2 항ìČŽ 및 읎의 용도
CN120647763A (zh) 2020-01-07 2025-09-16 é«˜èŻšç”Ÿç‰©ćŒ»èŻć…Źćž æŠ—ćŠäčłçł–ć‡é›†çŽ -9æŠ—äœ“ćŠć…¶ç”šé€”
TW202140473A (zh) 2020-01-15 2021-11-01 çŸŽć•†çșœćœ–è—„擁慬揾 Map4k1æŠ‘ćˆ¶ćŠ‘
TW202146393A (zh) 2020-03-03 2021-12-16 çŸŽć•†çšźć…‹é†«ç™‚ć…Źćž Eif4eæŠ‘ćˆ¶ćŠ‘ćŠć…¶ç”šé€”
CN115485302A (zh) 2020-03-09 2022-12-16 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ć…·æœ‰ćąžćŒșçš„æż€ćŠšć‰‚æŽ»æ€§çš„é’ˆćŻčcd40的抗䜓
KR20230005160A (ko) 2020-03-19 2023-01-09 ìčŽìŽë©”띌 쎄띌퓚틱슀 ìžìœ”íŹë ˆìŽí‹°ë“œ Mdm2 분핎제 및 읎의 용도
TW202140441A (zh) 2020-03-23 2021-11-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ç¶“ć–ä»Łäč‹ćŽæ°§ćŸș異ćČć“šć•‰ćŒ–ćˆç‰©
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 çŸŽć•†ć‡±éș„æ‹‰é†«ç™‚ć…Źćž Iraké™è§ŁćŠ‘äč‹ç”æ™¶ćž‹
CN111803635B (zh) * 2020-06-17 2023-03-14 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŸșçĄ€ćŒ»ć­Šç ”ç©¶æ‰€ ć°ćˆ†ć­æŠ‘ćˆ¶ć‰‚ćœšæČ»ç–—ć‘Œćžé“ç—…æŻ’æ€§è‚ș炎侊的ćș”甚
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN116133692A (zh) 2020-07-30 2023-05-16 懯éșŠæ‹‰ćŒ»ç–—ć…Źćž æȻ疗çȘć˜æ·‹ć·Žç˜€çš„æ–čæł•
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
CN116724051A (zh) 2020-08-10 2023-09-08 äžŠæ”·ćŻ»ç™ŸäŒšç”Ÿç‰©æŠ€æœŻæœ‰é™ć…Źćž 甹äșŽé€šèż‡é¶ć‘igsf8杄æȻ疗è‡Șèș«ć…ç–«æ€§ç–Ÿç—…ć’Œç™Œç—‡çš„ç»„ćˆç‰©ć’Œæ–čæł•
CA3186504A1 (en) 2020-08-17 2022-02-24 Stephen J. Blakemore Bicycle conjugates specific for nectin-4 and uses thereof
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3200814A1 (en) 2020-12-02 2022-06-09 Alfredo C. Castro Tead inhibitors and uses thereof
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
WO2022133083A1 (en) 2020-12-16 2022-06-23 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN116867758A (zh) 2020-12-30 2023-10-10 懯éșŠæ‹‰ćŒ»ç–—ć…Źćž Iraké™è§Łć‰‚ć’Œć…¶ç”šé€”
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
MX2023009060A (es) 2021-02-02 2023-09-29 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
AU2022221124A1 (en) 2021-02-12 2023-08-03 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
EP4291235A4 (en) 2021-02-12 2025-01-08 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
CN116867494A (zh) 2021-02-15 2023-10-10 懯éșŠæ‹‰ćŒ»ç–—ć…Źćž Irak4é™è§Łć‰‚ć’Œć…¶ç”šé€”
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
EP4052705A1 (en) 2021-03-05 2022-09-07 UniversitÀt Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4305041A1 (en) 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022253450A1 (en) 2021-04-05 2023-11-16 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
EP4320112B1 (en) 2021-04-06 2025-05-14 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
US12325697B2 (en) 2021-04-09 2025-06-10 Nimbus Clio, Inc. CBL-B modulators and uses thereof
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
KR20240020735A (ko) 2021-05-07 2024-02-15 ìčŽìŽë©”띌 쎄띌퓚틱슀 ìžìœ”íŹë ˆìŽí‹°ë“œ Cdk2 분핎제 및 ê·ž 용도
WO2023288254A1 (en) 2021-07-14 2023-01-19 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
US20240336630A1 (en) 2021-07-15 2024-10-10 Blueprint Medicines Corporation Map4k1 inhibitors
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
US20260028330A1 (en) 2022-08-02 2026-01-29 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
IL318577A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
KR20250056924A (ko) 2022-08-02 2025-04-28 멬믾널 ë°”ìŽì˜€ì‚ŹìŽì–žì‹œìŠ€ 멬믾티드 ìč˜í™˜ëœ í”ŒëŠŹëˆ gpr84 êžží•­ì œ 및 읎의 용도
CN119654312A (zh) 2022-08-08 2025-03-18 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 甚䜜tç»†èƒžæŽ»ćŒ–ć‰‚çš„ć–ä»Łçš„ć››ć”‘ćŸșćŒ–ćˆç‰©
CN119677740A (zh) 2022-08-09 2025-03-21 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 甚䜜tç»†èƒžæŽ»ćŒ–ć‰‚çš„ć”èƒșć–ä»Łçš„ćŒçŽŻćŒ–ćˆç‰©
JP2025526726A (ja) 2022-08-11 2025-08-15 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłïŒăƒ©ăƒ»ăƒ­ă‚·ăƒ„ăƒ»ă‚ąă‚Żăƒă‚§ăƒłă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ äșŒç’°ćŒăƒ†ăƒˆăƒ©ăƒ’ăƒ‰ăƒ­ă‚ąă‚Œăƒ”ăƒłèȘ˜ć°Žäœ“
AU2023322638A1 (en) 2022-08-11 2024-11-28 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
AU2023322637A1 (en) 2022-08-11 2024-11-14 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN116143726B (zh) * 2022-12-02 2024-09-06 ćčżć·žćž‚è”ç‘žćˆ¶èŻæœ‰é™ć…Źćž äž€ç§çŽŻçŁ·è…șè‹·æ‚èŽšçš„ćˆ¶ć€‡æ–čæł•
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
EP4511371A1 (en) 2023-05-08 2025-02-26 Bristol-Myers Squibb Company Substituted phenyl oxazolone compounds
EP4709712A1 (en) 2023-05-10 2026-03-18 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
AU2024281056A1 (en) 2023-05-31 2026-01-22 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
AU2024285766A1 (en) 2023-06-07 2026-01-08 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
AU2024312190A1 (en) 2023-06-23 2025-07-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
KR102834908B1 (ko) 2023-09-02 2025-07-16 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 ìč˜í™˜ëœ 페닐 ì˜„ì†Œì˜„ì‚ŹìĄžëŠŽ í”ŒíŽ˜ëŠŹë”˜ 디옚 í™”í•©ëŹŒ
JP7808733B2 (ja) 2023-09-13 2026-01-29 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ çœźæ›ă‚Șă‚­ă‚œă‚€ă‚œă‚€ăƒłăƒ‰ăƒȘăƒ‹ăƒ«ăƒ”ăƒšăƒȘă‚žăƒłïŒïŒ’ïŒŒïŒ–ïŒă‚žă‚ȘăƒłćŒ–ćˆç‰©
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
TW202535865A (zh) 2023-10-31 2025-09-16 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž æł›çŽ ç‰čç•°æ€§ćŠ ć·„è›‹ç™œé…¶1 (usp1) ćŒ–ćˆç‰©
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2026035787A1 (en) 2024-08-07 2026-02-12 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) macrocyles
WO2026080794A1 (en) 2024-10-11 2026-04-16 Bristol-Myers Squibb Company Chemical compounds useful for degrading proteins
CN119707950A (zh) * 2024-12-24 2025-03-28 æ— é”Ąćž‚ć—äșŹć€§ć­Šé”Ąć±±ćș”ç”šç”Ÿç‰©æŠ€æœŻç ”ç©¶æ‰€ 侀种甹äșŽć…ç–«è›‹ç™œé¶ć‘é™è§Łçš„ć”Œćˆäœ“ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE40106T1 (de) 1983-05-18 1989-02-15 Ciba Geigy Ag Cyclohexandion-carbonsaeurederivate mit herbizider und das pflanzenwachstum regulierender wirkung.
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
CA2483451C (en) 2002-04-12 2014-07-29 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JP2007520559A (ja) 2004-02-03 2007-07-26 ă‚ąăƒœăƒƒăƒˆăƒ»ăƒ©ăƒœăƒ©ăƒˆăƒȘăƒŒă‚ș æČ»ç™‚è–Źăšă—ăŠăźă‚ąăƒŸăƒŽăƒ™ăƒłă‚Ÿă‚Șă‚­ă‚”ă‚ŸăƒŒăƒ«éĄž
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US8389568B2 (en) 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
DE102007020493A1 (de) 2007-04-30 2008-11-06 GrĂŒnenthal GmbH Substituierte Amid-Derivate
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
EA201001030A1 (ru) 2007-12-19 2011-02-28 ĐĐŒĐłĐ”Đœ Đ˜ĐœĐș. ĐšĐŸĐœĐŽĐ”ĐœŃĐžŃ€ĐŸĐČĐ°ĐœĐœŃ‹Đ” ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžŃ ĐżĐžŃ€ĐžĐŽĐžĐœĐ°, ĐżĐžŃ€ĐžĐŒĐžĐŽĐžĐœĐ° Đž Ń‚Ń€ĐžĐ°Đ·ĐžĐœĐ° ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€ĐŸĐČ ĐșĐ»Đ”Ń‚ĐŸŃ‡ĐœĐŸĐłĐŸ цоĐșла
CA2722159C (en) * 2008-04-24 2016-04-05 Newlink Genetics Corporation Substituted phenylimidazole compounds and their use as ido inhibitors
JP5465720B2 (ja) 2008-07-08 2014-04-09 ă‚€ăƒłă‚”ă‚€ăƒˆăƒ»ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œăźé˜»ćźłć‰€ăšă—ăŠăźïŒ‘ïŒŒïŒ’ïŒŒïŒ•âˆ’ă‚Șă‚­ă‚”ă‚žă‚ąă‚ŸăƒŒăƒ«
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
NO2694640T3 (https=) * 2011-04-15 2018-03-17
KR20150087400A (ko) 2012-11-20 2015-07-29 ëČ„í…ìŠ€ 파마슈티ìčŒìŠ€ ìžìœ”íŹë ˆìŽí‹°ë“œ ìžëŒì•„ëŻŒ 2,3-디옄시êČŒë‚˜ì œì˜ ì–”ì œì œëĄœì„œ 유용한 í™”í•©ëŹŒ
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
KR20150126623A (ko) 2013-03-14 2015-11-12 뉮링크 제넀틱슀 윔퍌레읎션 튞늜토판 ëŒ€ì‚ŹëĄœ 읞한 멎역얔제의 ì–”ì œì œëĄœì„œì˜ 삌환식 í™”í•©ëŹŒ
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
EA031470B1 (ru) 2013-03-15 2019-01-31 Đ‘Ń€ĐžŃŃ‚ĐŸĐ»-МаĐčДрс ĐĄĐșĐČОбб ĐšĐŸĐŒĐżĐ°ĐœĐž Đ˜ĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Ń‹ ido
EP2970114B1 (en) 2013-03-15 2019-05-15 Bristol-Myers Squibb Company Ido inhibitors
MX2015017486A (es) 2013-07-01 2016-03-21 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (dio).
ES2707961T3 (es) 2013-07-11 2019-04-08 Bristol Myers Squibb Co Inhibidores de IDO

Also Published As

Publication number Publication date
AU2016277574A1 (en) 2017-01-12
NZ616457A (en) 2015-05-29
HK1256355A1 (en) 2019-09-20
KR102164443B1 (ko) 2020-10-12
HK1193822A1 (zh) 2014-10-03
CA2833296A1 (en) 2012-10-18
HRP20180335T1 (hr) 2018-04-20
MX340442B (es) 2016-07-08
CN103547579A (zh) 2014-01-29
CA2833296C (en) 2020-12-08
JP2016029092A (ja) 2016-03-03
EP3348558A1 (en) 2018-07-18
PL3018132T3 (pl) 2018-05-30
EP3018132A1 (en) 2016-05-11
PE20141124A1 (es) 2014-09-06
AU2012242871A1 (en) 2013-10-31
AU2012242871B2 (en) 2014-09-11
EP3018132B1 (en) 2017-12-13
AU2018202706A1 (en) 2018-05-10
RS56992B1 (sr) 2018-05-31
US20190225618A1 (en) 2019-07-25
ME02417B (me) 2016-09-20
MX2013012021A (es) 2014-07-10
JP5837673B2 (ja) 2015-12-24
CN105111210A (zh) 2015-12-02
PT3018132T (pt) 2018-03-09
HK1223371A1 (en) 2017-07-28
ES2569665T3 (es) 2016-05-12
AU2016277574B2 (en) 2018-04-19
RS54723B1 (sr) 2016-08-31
CN103547579B (zh) 2017-02-15
CO6862146A2 (es) 2014-02-10
US9260434B2 (en) 2016-02-16
WO2012142237A8 (en) 2012-11-22
US20180118753A1 (en) 2018-05-03
AU2014274564A1 (en) 2015-01-22
ES2660831T3 (es) 2018-03-26
HUE027316T2 (en) 2016-10-28
IL228862A (en) 2015-10-29
RU2013150811A (ru) 2015-05-20
US20140066625A1 (en) 2014-03-06
AU2012242871A8 (en) 2013-11-21
AU2014274564B2 (en) 2016-10-06
DK2697227T3 (en) 2016-04-25
JP2017149769A (ja) 2017-08-31
CY1117440T1 (el) 2017-04-26
US9388191B2 (en) 2016-07-12
JP2014511876A (ja) 2014-05-19
CN105111210B (zh) 2018-10-09
HUE038586T2 (hu) 2018-10-29
NZ708090A (en) 2016-12-23
IL241846A0 (en) 2015-11-30
US20160362412A1 (en) 2016-12-15
IL246515B (en) 2018-08-30
IL228862A0 (en) 2013-12-31
NZ723271A (en) 2018-03-23
PL2697227T3 (pl) 2016-09-30
SMT201600130B (it) 2016-07-01
US9850248B2 (en) 2017-12-26
SI3018132T1 (en) 2018-04-30
IL241846A (en) 2016-06-30
HRP20160369T1 (hr) 2016-06-03
JP6145491B2 (ja) 2017-06-14
EP2697227B1 (en) 2016-02-03
EP2697227A1 (en) 2014-02-19
RU2613579C2 (ru) 2017-03-17
KR20140059167A (ko) 2014-05-15
RU2017107026A3 (https=) 2019-01-23
JP2015061877A (ja) 2015-04-02
NO2694640T3 (https=) 2018-03-17
BR112013026494A2 (pt) 2016-12-27
CL2013002990A1 (es) 2014-07-04
WO2012142237A1 (en) 2012-10-18
DK3018132T3 (en) 2018-03-12
LT3018132T (lt) 2018-03-26
US20160002249A1 (en) 2016-01-07
RU2017107026A (ru) 2019-01-23
US10233190B2 (en) 2019-03-19
PE20181023A1 (es) 2018-06-27
AU2012242871C1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
IL246515B (en) Imidazole derivatives are designed for use as ido inhibitors
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
SG10201601802YA (en) Dispiropyrrolidine derivatives
IL233366A (en) Tetra- or phentocyclo-pyridopathalazines are digested as parp inhibitors
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
IL233365A0 (en) Tetra or pentacyclic dihydrodiazepinocarbazolones are conjugated as parp inhibitors
IL228949A0 (en) History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
IL258704B (en) History of hydantoins used as kv3 inhibitors
IL247639B (en) History of heteroaryl piperidine
IL229990A0 (en) History of n-oxypyrazolo-triazapine-dione
EP2744788A4 (en) BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS
EP2703403A4 (en) imidazole
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
PT2721009E (pt) Derivados de pirazole Ășteis como inibidores de aldosterona sintase
HK1186463A (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201209319B (en) Cyclopropyl-indole derivatives
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201120474D0 (en) Inhibitors
GB201100183D0 (en) Fused aminodihydropyrimidone derivatives